Friday - June 19, 2026

Category Archives: Science

Spinocerebellar Ataxias Pipeline Gains Momentum with 10+ Emerging Therapies Across Clinical Development, Driven by Advances in Gene-Silencing and Regenerative Medicine

The Spinocerebellar Ataxias pipeline landscape is witnessing significant progress, fueled by increasing research into gene-targeted therapies, antisense oligonucleotides, stem cell-based approaches, and disease-modifying treatment strategies. Growing scientific understanding of the genetic mechanisms underlying Spinocerebellar Ataxias is encouraging the development of … Continue reading →

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the HPV+ Recurrent/Metastatic Head and Neck Cancer … Continue reading →

Urinary Tract Infections Pipeline Shows Strong Momentum as 38+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Urinary Tract Infections Pipeline Insight 2026” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in the Urinary Tract Infections pipeline landscape. It covers the Urinary Tract Infections Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Oncolytic Virus Cancer Therapy Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2026” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical … Continue reading →

Eosinophilic Esophagitis Pipeline Shows Strong Momentum as 25+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insights 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Acromegaly Pipeline Shows Strong Momentum as 8+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Acromegaly Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acromegaly pipeline … Continue reading →

Small Cell Lung Cancer Pipeline Shows Strong Momentum as 100+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading →

Charcot Marie Tooth Pipeline Shows Strong Momentum as 13+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Charcot Marie Tooth Disease Pipeline Insight, 2026” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Charcot Marie Tooth Disease pipeline landscape. It covers the Charcot Marie Tooth pipeline drug profiles, including clinical and nonclinical stage … Continue reading →

Hemophagocytic Lymphohistiocytosis Market Size is Expected to Witness Robust Growth by 2036 Driven by Emerging Targeted Therapies and Expanding Treatment Landscape | DelveInsight

The Hemophagocytic Lymphohistiocytosis (HLH) Market is anticipated to experience substantial growth through 2036, driven by increasing disease recognition, improving diagnostic rates, growing adoption of targeted therapies, and the expected launch of novel pipeline candidates. The emergence of therapies such as … Continue reading →

Myelofibrosis Market is Projected to Grow Significantly by 2036 Owing to the Launch of Novel Disease-Modifying Therapies | DelveInsight

The market dynamics for Myelofibrosis are witnessing substantial growth driven by the increasing prevalence of the disease, rising adoption of JAK inhibitors, growing awareness of myeloproliferative neoplasms, and the development of innovative disease-modifying therapies. Additionally, the launch of emerging therapies … Continue reading →